Profile data is unavailable for this security.
About the company
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing treatments for patients battling cancer. The Company develops a targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. Its lead radiotherapeutic candidate, Rhenium (186Re) obisbemeda is designed specifically to CNS cancers including recurrent glioblastoma (GBM), leptomeningeal metastases (LM), and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. The Company’s Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. The Company’s portfolio also includes 188RNL-BAM, a radioembolization therapy for liver cancer.
- Revenue in USD (TTM)224.00k
- Net income in USD-20.28m
- Incorporated1997
- Employees17.00
- LocationPlus Therapeutics Inc4200 Marathon Blvd Ste 200AUSTIN 78756-3433United StatesUSA
- Phone+1 (858) 458-0900
- Fax+1 (302) 636-5454
- Websitehttp://www.plustherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nexgel Inc | 2.06m | -5.74m | 9.05m | 10.00 | -- | 1.10 | -- | 4.40 | -1.03 | -1.03 | 0.3693 | 1.47 | 0.2545 | 5.23 | 8.99 | 205,800.00 | -70.94 | -- | -90.70 | -- | 16.08 | -- | -278.77 | -- | 7.10 | -1.57 | 0.0333 | -- | 130.12 | -- | -90.37 | -- | -- | -- |
| Aptinyx Inc | 0.00 | -72.41m | 9.14m | 40.00 | -- | 0.1874 | -- | -- | -1.07 | -1.07 | 0.00 | 0.7205 | 0.00 | -- | -- | 0.00 | -69.34 | -46.41 | -72.45 | -48.50 | -- | -- | -- | -1,506.55 | -- | -32.83 | 0.3362 | -- | -36.06 | -36.64 | -49.61 | -- | -- | -- |
| Lucira Health Inc | 212.13m | -143.28m | 9.14m | 221.00 | -- | 0.1496 | -- | 0.0431 | -3.59 | -3.59 | 5.27 | 1.51 | 1.03 | 4.99 | 16.13 | 1,504,497.00 | -69.56 | -- | -94.88 | -- | -16.03 | -- | -67.54 | -- | 0.7858 | -87.12 | 0.3257 | -- | 34,492.94 | -- | -73.58 | -- | -- | -- |
| China Health Industries Holdings, Inc. | 32.65k | 713.81k | 9.18m | 45.00 | 12.84 | 0.2183 | 6.11 | 281.03 | 0.0109 | 0.0109 | 0.0005 | 0.6413 | 0.0006 | 0.048 | 1.12 | 725.56 | 1.39 | 3.15 | 1.64 | 3.82 | 9.19 | 62.71 | 2,186.25 | 23.18 | 6.68 | -- | 0.1189 | -- | -100.00 | -86.65 | -127.41 | -- | -- | -- |
| Halberd Corp | 281.24k | 25.34k | 9.22m | 3.00 | 7.03 | -- | 363.57 | 32.80 | 0.0023 | 0.0023 | 0.0018 | -0.0002 | 0.1449 | 0.0303 | 2.52 | -- | 1.31 | -- | 4.58 | -- | 50.00 | -- | 9.01 | -- | 0.2661 | 1.35 | 1.02 | -- | 271.52 | -- | -60.11 | -- | -- | -- |
| Novelstem International Corp | 424.75k | 6.25m | 9.38m | 15.00 | 0.7251 | 0.1489 | 1.48 | 22.07 | 0.2758 | 0.2758 | 0.0188 | 1.34 | 0.0146 | -- | 21.58 | -- | 21.53 | -9.02 | 22.48 | -12.13 | -- | -- | 1,472.13 | -168.94 | -- | -- | 0.0011 | -- | -31.09 | -41.39 | 580.92 | -- | -- | -- |
| Navidea Biopharmaceuticals Inc | 65.66k | -17.22m | 9.38m | 11.00 | -- | -- | -- | 142.89 | -0.5576 | -0.5576 | 0.0021 | -0.2624 | 0.0119 | -- | -- | -- | -275.54 | -169.68 | -- | -753.52 | -181.68 | 91.34 | -23,114.79 | -1,938.53 | -- | -12.79 | -- | -- | -87.65 | -48.49 | -46.75 | -- | -- | -- |
| Aptevo Therapeutics Inc | 6.78m | 5.58m | 9.47m | 54.00 | 1.74 | 0.6007 | 1.44 | 1.40 | 1.07 | 1.24 | 1.36 | 3.10 | 0.1417 | -- | 4.38 | 125,537.00 | 11.66 | -51.87 | 20.10 | -75.99 | -- | -- | 82.31 | -349.18 | -- | -- | 0.1988 | -- | 185.26 | 4.24 | 4.90 | -- | -22.27 | -- |
| Virpax Pharmaceuticals Inc | 0.00 | -21.65m | 9.59m | 7.00 | -- | 0.5786 | -- | -- | -1.85 | -1.85 | 0.00 | 1.42 | 0.00 | -- | -- | 0.00 | -73.09 | -- | -80.09 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -79.58 | -- | -- | -- |
| Cyclo Therapeutics Inc | 1.77m | -13.26m | 9.60m | 9.00 | -- | 1.37 | -- | 5.41 | -1.62 | -1.62 | 0.2174 | 0.6638 | 0.1812 | 0.7886 | 4.73 | 197,120.00 | -135.45 | -114.25 | -199.60 | -174.73 | 88.33 | 89.97 | -747.59 | -676.15 | 2.83 | -- | 0.00 | -- | 75.54 | 1.08 | -59.78 | -- | 19.22 | -- |
| Plus Therapeutics Inc | 224.00k | -20.28m | 9.73m | 17.00 | -- | 1.43 | -- | 43.42 | -0.787 | -0.787 | 0.0085 | 0.1918 | 0.0098 | -- | -- | 13,176.47 | -88.44 | -53.03 | -144.17 | -121.85 | -- | -- | -9,051.34 | -407.87 | -- | -35.01 | 0.4556 | -- | -- | -48.87 | -51.32 | -- | -19.40 | -- |
| Theriva Biologics Inc | 0.00 | -19.70m | 9.98m | 16.00 | -- | 0.1801 | -- | -- | -1.35 | -1.35 | 0.00 | 3.67 | 0.00 | -- | -- | 0.00 | -25.17 | -38.93 | -27.61 | -47.48 | -- | -- | -- | -- | -- | -- | 0.0044 | -- | -- | -- | -84.67 | -- | -52.33 | -- |
| Imunon Inc | 500.00k | -26.89m | 10.04m | 29.00 | -- | 0.2318 | -- | 20.07 | -4.28 | -4.28 | 0.078 | 5.83 | 0.0071 | -- | 14.51 | 17,241.38 | -38.41 | -41.05 | -43.00 | -48.59 | -- | -- | -5,377.37 | -3,655.60 | -- | -4.93 | 0.1265 | -- | 0.00 | 0.00 | 3.32 | -- | 37.89 | -- |
| Galmed Pharmaceuticals Ltd | 0.00 | -22.68m | 10.08m | 19.00 | -- | 0.6403 | -- | -- | -0.903 | -0.903 | 0.00 | 0.6249 | 0.00 | -- | -- | 0.00 | -69.60 | -39.00 | -84.33 | -43.35 | -- | -- | -- | -3,325.46 | -- | -- | 0.00 | -- | -- | -- | -12.85 | -- | -8.34 | -- |
| Neximmune Inc | 0.00 | -61.14m | 10.30m | 74.00 | -- | 0.2159 | -- | -- | -2.64 | -2.64 | 0.00 | 1.83 | 0.00 | -- | -- | 0.00 | -75.38 | -- | -84.10 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -54.70 | -- | -- | -- |
| Context Therapeutics Inc | 0.00 | -14.84m | 10.31m | 9.00 | -- | 0.2966 | -- | -- | -0.9292 | -0.9292 | 0.00 | 2.18 | 0.00 | -- | -- | 0.00 | -33.24 | -- | -35.74 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -41.88 | -- | -- | -- |
Data as of Mar 27 2023. Currency figures normalised to Plus Therapeutics Inc's reporting currency: US Dollar USD
7.60%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2022 | 1.09m | 3.25% |
| Parkman Healthcare Partners LLCas of 31 Dec 2022 | 583.47k | 1.74% |
| Geode Capital Management LLCas of 31 Dec 2022 | 258.05k | 0.77% |
| Schonfeld Strategic Advisors LLCas of 31 Dec 2022 | 190.40k | 0.57% |
| Millennium Management LLCas of 31 Dec 2022 | 136.90k | 0.41% |
| BlackRock Fund Advisorsas of 31 Dec 2022 | 104.43k | 0.31% |
| Renaissance Technologies LLCas of 31 Dec 2022 | 78.37k | 0.23% |
| Two Sigma Securities LLCas of 31 Dec 2022 | 40.75k | 0.12% |
| SSgA Funds Management, Inc.as of 31 Dec 2022 | 34.41k | 0.10% |
| Great Valley Advisor Group, Inc.as of 31 Dec 2022 | 33.60k | 0.10% |
More ▼
Data from 31 Dec 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
